Table 3. Treatment-related AEs in all patients who received combination therapy of PD-1 inhibitors and antiangiogenic agents.
| AEs | Grade 1, n [%] | Grade 2, n [%] | Grade 3, n [%] |
|---|---|---|---|
| General disorders | |||
| Decreased appetite | 1 [10] | 1 [10] | |
| Fatigue | 2 [20] | ||
| Headache | 1 [10] | ||
| Dermatological toxicity | |||
| Rash | 1 [10] | 1 [10] | |
| Hand-foot syndrome | 1 [10] | 1 [10] | |
| Hematological toxicity | |||
| Thrombocytopenia | 1 [10] | ||
| Leukopenia | 1 [10] | ||
| Gastrointestinal toxicity | |||
| Diarrhea | 1 [10] | ||
| Endocrine toxicity | |||
| Hypothyroidism | 1 [10] | ||
| Renal toxicity | |||
| Proteinuria | 2 [20] | 2 [20] | |
| Hypertension | 1 [10] | 1 [10] | |
| Hepatotoxicity | |||
| GGT increased | 3 [30] | ||
| AST increased | 1 [10] | ||
| ALT increased | 1 [10] | ||
AEs, adverse events; PD-1, programmed death 1; GGT, glutamyl transpeptidase; AST, aspartate aminotransferase; ALT, alanine aminotransferase.